Artiva Biotherapeutics Presents Updated Clinical, Safety And Translational Data For AlloNK In Combination With Rituximab At 17th ISSjD 2026 In Paris

Artiva Biotherapeutics presented updated clinical data for AlloNK in combination with rituximab at the 17th ISSjD 2026 in Paris. As of July 2, 2026, the data showed a mean stimulated salivary flow increase from 0.4 to 1.1 mL/min in eight patients with baseline hyposalivation. Safety data from 73 Phase 2a study patients indicated no occurrences of cytokine release syndrome or treatment discontinuations due to adverse events, supporting the potential for outpatient administration.